|
CPEB3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62470037423645E-12 |
| Normal-vs-Stage2 |
1.141800000104E-07 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
1.219650E-02 |
| Stage1-vs-Stage3 |
2.656800E-01 |
| Stage1-vs-Stage4 |
3.188800E-04 |
| Stage2-vs-Stage3 |
1.839810E-03 |
| Stage2-vs-Stage4 |
3.53659999999811E-05 |
| Stage3-vs-Stage4 |
3.972300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.74210001979702E-09 |
| Normal-vs-Asian |
8.88178419700125E-16 |
| Caucasian-vs-AfricanAmerican |
3.999800E-01 |
| Caucasian-vs-Asian |
9.978800E-01 |
| AfricanAmerican-vs-Asian |
4.834800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62525548574877E-12 |
| Male-vs-Female |
8.339600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(81-100Yrs) |
3.47460000005295E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.775600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.897400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.977000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.262400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.409200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.461200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.70779999999682E-05 |
| Classical-VS-Follicular |
3.04579999999E-06 |
| Classical-VS-Other |
5.440200E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
7.78880293594852E-11 |
| Tall-VS-Other |
2.469000E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
3.061200E-03 |
| Follicular-VS-Normal |
4.6724000002385E-08 |
| Other-VS-Normal |
6.40559999487422E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
3.591200E-04 |
|
|
